hers semaglutide shortage Hims & stock falls 25% as FDA curtails compounded GLP-1s Hims & Hers shares fall

Recent clinical trials (following patients for up to 68 weeks) are showing no significant long-term safety concerns

Conclusion Alkem Laboratories launch of Indias first single-shot pre-filled semaglutide syringe marks a major milestone in the countrys diabetes and obesity care landscape

1 4 The role of GLP-1 RAs in diabetes treatment has evolved over time since their initial US Food and Drug Administration (FDA) approval in 2005

By slowing gastric emptying, semaglutide prolongs the feeling of fullness after eating, which can lead to a reduction in food intake and, consequently, weight loss

Patients switching from tirzepatide should be mindful of the slight differences in the devices used for administering each medication

10.3389/fphar.2024.1372399 [DOI] [PMC free article] [PubMed] [Google Scholar] Liu J., An J., Jiang N., Yang K., Guan C., Zhao N., et al